JAZZ PHARMACEUTICALS PUBLIC LIMITED COMPANY (JAZZ)

Jazz Pharmaceuticals’ neuroscience division provides stable revenue, with Epidiolex reaching blockbuster status and Xywav contributing to the sleep disorder franchise. The company’s business quality is reflected in its impressive gross profit margins of 91.5%, according to InvestingPro data. An Inve…

The key attraction lies in its ... the stock is priced below its potential compared to both its industry peers and the broader market. ... The primary driver for JAZZ’s inclusion in the 'Decent Value' screen is its standout valuation score of 8/10. This is the strongest pillar in its fundamental rep…

Bernstein SocGen reiterates Jazz Pharmaceuticals stock rating at Market Perform

The target price range of $196.00 ... on the stock’s future valuation, offering investors a wide scope for potential gains. While the company’s P/E ratio and PEG ratio are currently unavailable, the forward P/E of 9.27 suggests that Jazz Pharmaceuticals is valued attractively relative to its forward…

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.